Jefferies raised estimates sharply on Medivation (NASDAQ: MDVN) after its latest prostate cancer survey suggested increased Xtandi market share in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE